GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer
Primovax - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.
Sponsor: CIRION Central Laboratory
Terminated
Preliminary data showed no survival benefit in the GV1001 group compared to the gemcitabine group.
This PHASE3 trial investigates Advanced Unresectable Pancreatic Cancer and is currently terminated or withdrawn. CIRION Central Laboratory leads this study, which shows 12 recorded versions since 2006 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 7 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2019 — Nov 2020 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2019 [monthly]
Terminated PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Jun 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CIRION Central Laboratory
- Dorevitch
- ICON Clinical Research
- ORION Clinical Services
- Pharmexa A/S
- Syneos Health
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus, Denmark , Amsterdam, Netherlands , Ancona, Italy , Angers, France , Auchenflower QLD, Australia , Austin, United States , Barcelona, Spain , Bedford Park, Australia , Bergen, Norway , Bialystok, Poland and 63 more locations